New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline

Journal of Neural Transmission, Supplement

Volumn , Issue 48, 1996, Pages 7-21

  Gerlach, M ^a,b   Desser, H ^c   Youdim, M B H ^d   Riederer, P ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; EXCITOTOXIN; FREE RADICAL; GLUTAMATE RECEPTOR; NEUROPROTECTIVE AGENT; SELEGILINE; 4 AMINOBUTYRIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTOXIN; NOOTROPIC AGENT; POLYAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; HUMAN; HUMAN TISSUE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; BINDING SITE; BIOSYNTHESIS; CLINICAL TRIAL; CORPUS STRIATUM; DISEASE COURSE; DRUG EFFECT; METABOLISM; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY;

BINDING SITES; CLINICAL TRIALS; CORPUS STRIATUM; DISEASE PROGRESSION; GAMMA-AMINOBUTYRIC ACID; HUMANS; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NOOTROPIC AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; POLYAMINES; RECEPTORS, N-METHYL-D-ASPARTATE; SELEGILINE; SUBSTANTIA NIGRA;

EID: 0030300159     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-7494-4_2     Document Type: Review

References (13)

1. + induced oxygen radical formation with mitochondrial enzymes. Free Rad Biol Med 15: 181-186
2. Albin RL, Makowiec RL, Hollingworth ZR, Dure LS, Penney Jr JB, Young AB (1992) Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 46: 35-48
3. Azmitia EC (1989) Nimodipine attenuates NMDA- and MDMA-induced toxicity of cultured fetal serotonergic neurons: evidence for a generic model of calcium toxicity. In: Traber J, Gispen WH (eds) Nimodipine and central nervous system function: new vistas. Schattauer, Stuttgart New York, pp 141-159
4. Beart PM, Schousboe A, Frandsen A (1995) Blockade by polyamine NMDA antagonists related to ifenprodil of NMDA-induced synthesis of cylic GMP, increases in calcium and cytotoxicity in cultured neurones. Br J Pharmacol 114: 1359-1364
5. Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical "Parkinsonism" in rats. J Neurochem 57: 2133-2135
6. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigro-striatal dopamine neurons. J Neurochem 56: 1441-1444
7. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455
8. R treatment in Parkinson's disease: a long-term study. J Neural Transm 64: 113-127
9. Bridges RJ, Koh J-Y, Hatalski CG, Cotman CW (1991) Increased excitotoxic vulnerability of cortical cultures with reduced levels of glutathione. Eur J Pharmacol 192: 199-220
10. Burckard WP, Gey KF, Pletscher A (1963) Diamine oxidase in polyamine catabolism. J Neurochem 10: 183-186
11. Chan PH, Chu L, Chen SF, Carlson EJ, Epstein CJ (1990) Reduced neurotoxicity in transgenic mice overexpressing human copper-zinc-superoxide dismutase. Stroke [Suppl III]21: III80-III82
12. Chiueh CC, Miyake H, Peng MT (1993) Role of dopamine autoxidation, hydroxyl radical generation and calcium overload in underlying mechanism involved in MPTP-in-duced parkinsonism. Adv Neurol 60: 251-258
13. Christoffersen CL, Meltzer LT (1995) Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors. Neuroscience 67:373-381